AACR: Celebrex Dramatically Reduces Adenoma Recurrence - CME Teaching Brief - MedPage Today
WASHINGTON, April 3- The selective Cox-2 inhibitor Celebrex (celecoxib) is effective in reducing recurrence of benign or precancerous adenomas in patients at a high risk of sporadic colorectal cancer, according to two large chemoprevention trials.
One investigator, Nadir Arbor, M.D., of Tel Aviv Sourasky Medical Center, called it "proof of principle that chemoprevention is feasible" in sporadic colon cancer.
Dr. Arbor presented results today of the international Prevention of Sporadic Adematous Polyps (PreSAP) trial at the American Association for Cancer Research meeting. Monica Bertagnolli, M.D., of the Dana-Farber Cancer Institute and Harvard Medical School presented results of the Adenoma Prevention with Celebrex (APC) trial.
Posted by gruwell at April 4, 2006 5:51 AM | TrackBack